JPS633786A - Collagen-containing capsule - Google Patents

Collagen-containing capsule

Info

Publication number
JPS633786A
JPS633786A JP61144784A JP14478486A JPS633786A JP S633786 A JPS633786 A JP S633786A JP 61144784 A JP61144784 A JP 61144784A JP 14478486 A JP14478486 A JP 14478486A JP S633786 A JPS633786 A JP S633786A
Authority
JP
Japan
Prior art keywords
solution
cells
collagen
salt
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP61144784A
Other languages
Japanese (ja)
Inventor
Junichiro Inoue
純一郎 井上
Kazuo Ueda
一夫 上田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asahi Chemical Industry Co Ltd
Original Assignee
Asahi Chemical Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Chemical Industry Co Ltd filed Critical Asahi Chemical Industry Co Ltd
Priority to JP61144784A priority Critical patent/JPS633786A/en
Publication of JPS633786A publication Critical patent/JPS633786A/en
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02Making microcapsules or microballoons
    • B01J13/06Making microcapsules or microballoons by phase separation
    • B01J13/10Complex coacervation, i.e. interaction of oppositely charged particles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

PURPOSE:Collagen-containing capsules multiplying cells in high density, obtained by covering a specific gelatinous composition with a film formed by bringing a fluid such as polyanion polysaccharide, etc., into contact with a solution of an edible chitin derivative, etc. CONSTITUTION:A medium for animal cell culture such as UEI mouse medium, etc., is optionally blended with an antibiotic to give a culture solution (A). Then NaOH and NaHCO3 are dissolved in water to give a solution (B). Then 5-20ml of 0.1-1wt% aqueous solution of I type collagen at pH 3 is blended with 0.5-3ml solution A, 0.5-3ml solution B and 0.5-3ml cell dispersion obtained by peeling off an animal cell (e.g. adhesion-dependent normal cell derived from human) with trypsin/PBS(-)(Dulbecco's) solution to give a gelatinous composition (C). Then, the component C is incorporated with 1-5wt% aqueous solution of polyanion polysaccharide (salt), cooled with ice and the prepared mixed solution is dripped through a needle having 100mum-1.5mm inner diameter to 0.5-5wt% aqueous solution of soluble chitin derivative (salt) of pH 6-7 to form the liquid drops into capsules.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は、細胞培養に関するものでちる。さらに詳しく
は、単位培養液あtり高密度に細胞を増殖させるカプセ
ルに関するものである。
DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to cell culture. More specifically, the present invention relates to a capsule that allows cells to grow at high density in a unit culture medium.

(従来の技術) 細胞培養用のカプセルとしては、まず、アルギン酸カル
シウムゲルで一時的カプセルを作り1次に、恒久的な膜
を設は比後、再びゲルを液比させる2段階カプセル化法
(特公沼6O−38111)Kよるもの、また、細胞増
殖用培地を含んだ細胞懸濁液を可溶性キチン誘導体1次
はその塩を用いて1段階でカプセル比する方法(日経産
業新聞。
(Prior art) Capsules for cell culture are made using a two-step encapsulation method (first, a temporary capsule is made from calcium alginate gel, a permanent membrane is installed, and then the gel is mixed with a liquid again). Also, a method of encapsulating a cell suspension containing a cell growth medium in one step using a soluble chitin derivative and its salt (Nikkei Sangyo Shimbun).

昭和60年1月22日、特開昭6O−175539)が
知られて−る。
January 22, 1985, Japanese Unexamined Patent Publication No. 6O-175539) is known.

(発明が解決しようとする問題点) 従来の細胞培養用のカプセルのうち、2段階カブセル化
法(特公昭6O−38111)によるものの場合は、カ
プセル製造時の操作が煩雑で時間がかかるため、細胞九
対するダメージが大きい。
(Problems to be Solved by the Invention) Among conventional capsules for cell culture, in the case of the two-step encapsulation method (Japanese Patent Publication No. 6O-38111), the operation during capsule manufacturing is complicated and time-consuming. Great damage to 9 cells.

また、コラーゲンゲルa度が0.1重量−以下の場合、
ゲル化卆不十分な7t−af>Kゲル強度かたもてず。
In addition, when the collagen gel a degree is 0.1 weight or less,
Insufficient gelation 7t-af>K gel strength.

細胞によっては固定基質材料(三次元増殖マトリックス
)としての役割を果たすことができない。
Some cells cannot serve as a fixed matrix material (three-dimensional growth matrix).

したがって、単位培養液あたシ高密度の細胞を増殖させ
ることはできない。そこで、充分なゲル強度を得ようと
して0.1重量%以上の高濃度のコラーゲンゲ、1%−
を包括させようとした場合には、カプセル化工程が終了
する前にコラーゲンがゲル化してしまい、アルギン酸カ
ルシウムゲルの再液化が困雌となる。アルギン酸カルシ
ウムグルを再液fヒしないと、細胞の増殖に悪影III
を与える。
Therefore, it is not possible to grow cells at a high density per unit culture medium. Therefore, in order to obtain sufficient gel strength, collagen gel with a high concentration of 0.1% by weight or more, 1% -
If an attempt is made to encapsulate the collagen, the collagen will gel before the encapsulation process is completed, making it difficult to reliquefy the calcium alginate gel. If calcium alginate is not rehydrated, cell proliferation will be adversely affected.
give.

′ ま友、培地を含んだ細胞懸濁液を可溶性キチン誘導
体またはその塩を用いて1段階でカプセル化する方法(
日経産業新聞、昭和61年1月22日。
' Mayu, a method for encapsulating a cell suspension containing a culture medium in one step using a soluble chitin derivative or its salt (
Nikkei Sangyo Shimbun, January 22, 1986.

特開昭6O−175539)の場合は、芯部が流動体で
ある次め、接着依存性細胞の培養には適していない。
In the case of JP-A-6O-175539), since the core is a fluid, it is not suitable for culturing adhesion-dependent cells.

本発明者らは、十分なゲル強度を有するコラーゲングル
中においては、接着依存性細胞が三次元的に生育するこ
とに着目した。しかしながら、この場合、増殖とともに
コラーゲンゲルが収縮し。
The present inventors focused on the fact that adhesion-dependent cells grow three-dimensionally in collagen glue that has sufficient gel strength. However, in this case, the collagen gel contracts as it proliferates.

細胞が死滅してしまう。本発明者らは、支持体の存在下
で培養を行ない、この問題′に解決しt(特jlI紹6
O−162875)。
Cells die. The present inventors solved this problem by culturing in the presence of a support (Special JlI Introduction 6).
O-162875).

ぢらに検討の結果、コラーゲングルに細胞を埋め込み、
ポリアニオン多糖類ま几はその塩の羊独もしくはそれら
の混合物を基材とする流動体と。
As a result of further investigation, we embedded cells into collagen glue,
A polyanionic polysaccharide or a fluid based on its salt or a mixture thereof.

可溶性キチン訪導体またはその塩の溶液との接触により
形成され九皮膜で包括し、100μm〜51のカプセル
として培養し友ところ、カプセル内部に細胞の増殖が認
められ几。さらに培養ft継続すると、細胞は三次元的
に増殖し、ま九、カプセルの被膜が支持体の役割を果た
し、高密度に細胞が生育しているにもかかわらず、ゲル
収縮がまつ九<社められないことを発見し、本発明にい
tつた。
When the chitin was formed by contact with a solution of a soluble chitin conductor or its salt and was surrounded by a nine-layer membrane and cultured as a capsule of 100 μm to 51 μm, cell proliferation was observed inside the capsule. As the culture continues, the cells proliferate three-dimensionally, and the capsule coating acts as a support, causing the gel to shrink even though the cells are growing at a high density. This led to the discovery that this was not possible and led to the present invention.

(問題点を解決するための手段) 本発明は、動物細胞、該動物細胞培養用培地。(Means for solving problems) The present invention relates to animal cells and a medium for culturing the animal cells.

コラーゲンより成るゲル状組底物を、ポリアニオン多糖
類ま友はその塩の単独もしくはそれらの混合物を基材と
する流動体と、可溶性キチン肪導体またはその塩の溶液
との接触により形底された皮膜で包括したカプセルに関
するものである。
A gel-like composite material composed of collagen is formed by contacting a fluid based on a polyanionic polysaccharide salt alone or a mixture thereof with a solution of a soluble chitin fat conductor or a salt thereof. It concerns a capsule enclosed in a membrane.

本発明でb5妨物細胞とは、昆虫細抱、魚類細胞、両生
類細胞、爬虫類細心、鳥類細胞または哺乳類細胞であシ
、浮遊性細胞でも接着依存性細胞でもよい。着比、正常
細胞でもガン細胞でもよい。
In the present invention, b5 obstruction cells include insect cells, fish cells, amphibian cells, reptile cells, avian cells, or mammalian cells, and may be floating cells or adhesion-dependent cells. The attachment ratio may be normal cells or cancer cells.

哺乳類細胞のなかでも、マウス、ラット、チャイニーズ
ハムスター、ヒト、ウマ、サル、ウシ等ノ細胞がよく用
いられる。接着依存性細胞のなかでも繊維芽様細胞が用
いられ、その中でも正常2倍体細胞での効果が著しho 本発明における培地成分は、通常、動物細胞培養に使用
される一般的な培地をいう。具体的には。
Among mammalian cells, mouse, rat, Chinese hamster, human, horse, monkey, and bovine cells are often used. Among adhesion-dependent cells, fibroblast-like cells are used, and among them, the effect on normal diploid cells is remarkable. say. in particular.

M E M 、メディウム(Medium ) j 9
9. Ham培地。
MEM, Medium j 9
9. Ham's medium.

DPMI−1640培地、ウェイマウス培地等、ま几は
それらの混合物が好ましい。場合によっては。
DPMI-1640 medium, Weymouth medium, etc., and mixtures thereof are preferred. In some cases.

これに動物血清およびビタミン、グロス7アクター等の
補填液を加えることもある。
To this, supplementary fluids such as animal serum and vitamins, Gross 7 Actor, etc. may be added.

本発明におけるコラーゲンは、1塁コラーゲンが主に用
いられる。Inコラーゲンの中でも、中性塩可溶性コラ
ーゲン、酸司溶性コラーゲン、酵素可溶性コラーゲン、
アテロコラーゲンが用いられる。
As the collagen in the present invention, first base collagen is mainly used. Among In collagen, neutral salt soluble collagen, acid soluble collagen, enzyme soluble collagen,
Atelocollagen is used.

lff1コラーゲンのafは0.1〜0.5重量%の範
囲が一般的であシ、この範囲金はずれると、細心の増殖
、に影#を与える。この範囲内で動物細胞の種類によっ
て最適なコラーゲンゲル濃度で、ゲルを被膜でカプセル
化することか可能である。ヒト正常2倍体繊維芽細胞の
場合は、0.2重th1%が最適である。
The af of lff1 collagen is generally in the range of 0.1 to 0.5% by weight, and if it deviates from this range, it will affect the careful growth. Within this range, it is possible to encapsulate the gel with a film at an optimal collagen gel concentration depending on the type of animal cell. For human normal diploid fibroblasts, 0.2 fold th1% is optimal.

本発明のポリアニオン多糖類またはその塩とは。What is the polyanionic polysaccharide or salt thereof of the present invention?

水溶液中でポリアニオン重合体となる多糖類まtはその
塩であって、低メトキシペクチン、カラゲナン、カルボ
キシメチルセルロース、アルギン酸。
Polysaccharides or salts thereof that form polyanionic polymers in aqueous solutions include low methoxy pectin, carrageenan, carboxymethyl cellulose, and alginic acid.

フンドロイチン硫酸等、またはその塩が好まし込。Fundroitin sulfate, etc., or its salts are preferred.

このなかでもカルボキシメチルセルロースナトリウムが
一般的である。
Among these, carboxymethylcellulose sodium is common.

本発明の可溶性キチン誘導体は、キチンに化学的処理を
行なって反応活性を高め九もので、キチンを脱アセチル
化処理して得られるキトサンまたはその塩がよい。場合
によっては、キトサンをさらに化学処理してメチル比、
サクシニル化する場合がある。可溶性キチン誘導体ま7
tはその塩の水溶液は、ポリイオン多糖類に特徴的な粘
弾性を示し、カプセル形成の際、カプセルの形状を球状
あるいは長球状に導く。
The soluble chitin derivative of the present invention can be obtained by chemically treating chitin to increase its reaction activity, and chitosan obtained by deacetylating chitin or a salt thereof is preferable. In some cases, chitosan is further chemically treated to improve the methyl ratio,
May be succinylated. Soluble chitin derivative 7
An aqueous solution of the salt of t exhibits viscoelasticity characteristic of polyionic polysaccharides, and upon capsule formation, the shape of the capsule is guided to a spherical or long spheroidal shape.

本発明のカプセルは、7tとえは、以下のようにして製
造する。
A 7 ton capsule of the present invention is manufactured as follows.

蒸留水1tK市販の粉末培地50〜200?および必要
に応じて抗生物質(アンビシリ/、ゲンタマイシン、タ
イロシン等1を程度まで)を加えて溶解し、濾過滅菌し
てA液とする。0.05 N水酸化ナトリウム水溶a1
00mlc、さらに炭酸水;l−トリウム1〜4fを加
え次ものか、あるいは0.08N水酸化ナトリウム水溶
液100sdiC1N−ヒドロキシエチルピペラジン−
N′−2−エタンスルホン酸2〜5fを溶かし、濾過滅
−してB液とする。
Distilled water 1tK Commercially available powdered medium 50-200? Then, if necessary, add antibiotics (Ambiciri, gentamicin, tylosin, etc. to a certain extent) to dissolve and sterilize by filtration to obtain Solution A. 0.05 N sodium hydroxide aqueous solution a1
00ml, then carbonated water; add 1-4f of l-thorium and add the following or 0.08N sodium hydroxide aqueous solution 100sdiC1N-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid 2-5f is dissolved and filtered to obtain liquid B.

コラーゲン全o、t〜1重iチ含んだp H3,0の水
溶液5〜20−に、水冷下上記のA液0.5〜3d、B
液0.5〜3−を順次加え、さらに、単層培養した動物
細胞を常法により、トリプシン−エチレンジアミン四酢
酸二ナトリウム/P B S(→(ダルベツコ)溶液あ
るいはトリプシン/PBS←)(ダルベツコ)溶液では
がし皮細胞@114液0.5〜3−を加えて攪拌する。
Add 0.5 to 3 d of the above solutions A and B to an aqueous solution of pH 3.0, 5 to 20, containing 0, t to 1 t of collagen, under water cooling.
Solution 0.5 to 3- were added sequentially, and the monolayer cultured animal cells were further treated with trypsin-ethylenediaminetetraacetic acid disodium/PBS (→ (Dulbetzko) solution or trypsin/PBS←) (Dulbetzco). In the solution, add 0.5 to 3 - 0.5 - 3 - peeled skin cells @114 solution and stir.

なお、コラーゲン水溶液は市販のCellmatrix
 (新田ゼラチン社製)ヲ使用するか、あるいはラット
尾けん、子牛皮などより抽出し調製したものを用いる。
The collagen aqueous solution is commercially available Cellmatrix.
(manufactured by Nitta Gelatin Co., Ltd.) or one extracted from rat tail, calf skin, etc.

混合液にポリアニオン多糖類またはその塩の1〜5重量
重量溶水溶液え均一に混合しt後、よく氷冷した状態で
可溶性キチン誘導体またはその塩の溶液の中に膚下し、
カプセルを形成させる。可溶性キチン誘導体ま九はその
塩は、溶液中に0.5〜5xii%含むのがよい。可溶
性キチン誘導体′1fcはその塩の溶液は、pH6,0
〜7.0に調整し、浸透圧を食塩で280〜590 m
osm K調整する。滴下に際しては、内径100μm
〜1.5!IIの針を用い、液滴を形成させ友後に、可
溶性キチン誘導体またはその塩の溶液に落下させる。落
下させると、 fLS表面のポリアニオン多糖類または
その塩は、可溶性キチン誘導体またはその塩とイオン結
合を起こし。
After uniformly mixing a 1 to 5 weight aqueous solution of a polyanionic polysaccharide or a salt thereof into the mixed solution, inject into a solution of a soluble chitin derivative or a salt thereof in a well-ice-cooled state,
Form a capsule. The soluble chitin derivative or its salt is preferably contained in the solution in an amount of 0.5 to 5xii%. The solution of the salt of soluble chitin derivative '1fc has a pH of 6.0.
Adjust the osmotic pressure to ~7.0 and adjust the osmotic pressure to 280-590 m with salt.
Adjust osm K. When dropping, the inner diameter is 100 μm.
~1.5! Using a No. II needle, a droplet is formed and then dropped into a solution of the soluble chitin derivative or its salt. When dropped, the polyanionic polysaccharide or its salt on the fLS surface forms an ionic bond with the soluble chitin derivative or its salt.

ゲル被膜を形成しカプセルとなる。表面に被膜ができる
と、可溶性キチン誘導体またはその塩は。
Forms a gel coating and becomes a capsule. When a film is formed on the surface, the soluble chitin derivative or its salt.

もはやカプセル内部に浸入することなく、このイオン結
合反応はカプセル表面で停止する。このようKして、カ
プセル内部はコラーゲンのゲルfヒに最適の条件が保持
される。
No longer penetrating into the capsule interior, this ionic bonding reaction stops at the capsule surface. In this manner, optimal conditions for collagen gelation are maintained inside the capsule.

場合によっては、これに空気層流を送9.液簡の微小比
をはかる場合もある。通常、100μm〜5鳳1程度の
ものが攪拌培養に適当である。形成されたカプセルは1
球状あるいは長球状で、30分程度で内部のコラーゲン
はゲルイヒする。ただし。
9. In some cases, a laminar air flow may be sent to this. In some cases, the minute ratio of liquid tablets is measured. Usually, a diameter of about 100 μm to 5 μm is suitable for agitation culture. The capsule formed is 1
It has a spherical or long spherical shape, and the collagen inside gels in about 30 minutes. however.

コラーゲンがl型以外のものは1通常、ゲルfヒを起こ
しにくいので、場合によってはI型との混合物を用いる
Since collagens other than type I usually do not cause gel flaw, a mixture with type I is used in some cases.

顕微鏡下で観察すると、膜の形成とその内部にコラーゲ
ンゲルにより三次元的に固定式れ九動物細胞が観察され
る。以上の操作は、すべて無菌的に行なう。この方法は
、そのままスケールアップすることができる。ま友、こ
れよシ小スケールでもよい。
When observed under a microscope, a membrane is formed and animal cells are observed three-dimensionally fixed within the membrane by collagen gel. All of the above operations are performed aseptically. This method can be directly scaled up. Friend, this can be done on a small scale.

以上の操作で製造し次カブ七ルは、攪拌培養器の中で、
該動物細胞培養用培地に懸濁させて用いる。カプセル内
に埋め込まれ7’C細砲は、V、拌によるせん断力から
保譲され、物理的にマイルドな1境に保たれる。
The next turnips produced by the above procedure are placed in a stirred culture vessel.
It is used by suspending it in the animal cell culture medium. The 7'C cannon embedded in the capsule is protected from the shear force caused by V and stirring, and is kept in a physically mild state.

1日間培養後、顕微鏡下で細胞の生前が認められる。式
らに培養を続けると、細胞は順調に増殖し、′;fi用
物質の生産に用いることができる。培養7日目のカプセ
ルの内部は、細胞が3次元的に増殖しているのが認めら
れ、コラーゲングルの効果が示され九。
After culturing for 1 day, viable cells can be observed under a microscope. If the culture is continued, the cells will proliferate smoothly and can be used for producing substances for ';fi. Three-dimensional proliferation of cells was observed inside the capsule on the 7th day of culture, demonstrating the effect of the collagen glue9.

産生し几有用物質は、カプセル被膜の分子透過上限によ
って、カプセル内部に蓄積させることもでき、また、カ
プセル外部に放出させることもできる。カプセル被膜の
分子透過上限は、ポリアニオン多糖類ま几はその塩の単
独もしくはそれらの混合物の濃度、および可溶性キチン
誘導体’i友はその塩のa度によってコントロールでき
る。
The produced useful substances can be accumulated inside the capsule or can be released outside the capsule depending on the upper limit of molecular permeability of the capsule coat. The upper molecular permeability limit of the capsule coating can be controlled by the concentration of the polyanionic polysaccharide salt alone or in a mixture thereof, and by the a degree of the salt of the soluble chitin derivative.

(発明の効果) カプセルに動物細胞を該動物細胞培養用培地およびコラ
ーゲンゲルとともに封じ込め、該動物細胞培養用培地中
で浮遊攪拌すると、z、oxtoscells/TRt
gelで植込み、最大5.OX 10フcells/a
1tgel’jで増殖シ友。
(Effect of the invention) When animal cells are sealed in a capsule together with the animal cell culture medium and collagen gel and suspended and stirred in the animal cell culture medium, z, oxtocells/TRt
Implant with gel, maximum 5. OX 10 cells/a
Proliferate with 1tgel'j.

(実施例) 実施例1 イーグル(Eagle’s ) M E M粉末(フロ
ー)ヲ96 t/l、アンピシリンを5001L9/l
の濃度で蒸留水に溶解し、濾過滅菌し之。この溶液をA
液とじ比ゆ 0.05 N水酸化ナトリウム水溶液100−に重炭酸
ナトリウム2,29.N−ヒドロキシエチルピペラジン
−N′−2−エタンスルホン酸4.77ft−溶かし、
濾過滅菌し友。この溶液をB液とした。
(Example) Example 1 Eagle's MEM powder (flow) 96 t/l, ampicillin 5001 L9/l
Dissolved in distilled water at a concentration of , and filter sterilized. This solution is A
Liquid binding ratio 0.05 N sodium hydroxide aqueous solution 100% to sodium bicarbonate 2.29%. N-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid 4.77ft-dissolved,
Filter sterilization friend. This solution was designated as Solution B.

Cel 1matrix I A (新田ゼラチ7 、
3,01L9 / td 。
Cel 1matrix I A (Nitta Gelachi 7,
3,01L9/td.

pH5,0) 14,1dVcs氷冷下A液2dとB液
2−を順次加え、さらに単層培養したHEL細胞(大日
本裂薬)を常法により、濾過滅菌したトリプシン−エチ
レンジアミン四酢酸二ナトリウム/PBS(−)(ダル
ベツコ)溶液ではがし′fi−細胞懸濁液(2,OX 
10’ cells/d ) 2 td f加え攪拌L
lt。
pH 5,0) 14,1 dVcs Under ice-cooling, 2 d of solution A and 2 d of solution B were added sequentially, and monolayer cultured HEL cells (Dainippon Hiroyaku Co., Ltd.) were filter-sterilized using disodium trypsin-ethylenediaminetetraacetate. / PBS(-) (Dulbetzko) solution and peel off'fi- cell suspension (2,OX
10' cells/d) Add 2 td f and stir L
lt.

この溶液[5重量%カルボキシメチルセルロースナトリ
ウム塩水溶液2dft加え、泡をたてないよう均一に混
合し、この溶液6cとし比ゆ一方、キトサン塩酸塩の2
重量係水溶液を調製し、アルカリを加えてp H6,0
とし、NaC4で浸透圧f 290 mosm K調整
し友。この溶液5〇−に、上記の溶液cl攪拌下、内径
0.51IIの針を通してゆつくシ滴下し、平均粒径2
m冨のカプセルを形成させた。得られたカプセルを、胎
児牛血清10%に含むイーグル(Eagle’s ) 
MEM培地4〇−中で、5チ炭酸ガAを含む空気の存在
下1’(37Cで攪拌培養し友。容器は100d容量の
スピナーフラスコ(索出科学)を用い1回転速度S O
rpmで行なつ几。
Add 2 dft of this solution [5 wt% carboxymethylcellulose sodium salt aqueous solution and mix uniformly without forming bubbles, and use this solution as solution 6c.
Prepare a weight-related aqueous solution and add alkali to adjust the pH to 6.0.
Then, adjust the osmotic pressure f 290 mosm K with NaC4. To this solution 50-, the above solution Cl was slowly added dropwise through a needle with an inner diameter of 0.51 II while stirring, and the average particle size was 2.
m-rich capsules were formed. Eagle's capsules were added to 10% fetal bovine serum.
Culture in MEM medium 40°C with stirring in the presence of air containing 5% carbon dioxide A at 1' (37C).The container is a spinner flask (Sakude Kagaku) with a capacity of 100 d, and the container is 1 rotation speed SO.
Run at rpm.

10日間培養後に4.OX 10フcells/11I
tgelの細胞密度を得友。HEL細胞のかわりに、M
Lg細胞(ddYマウス肺細胞二大日本M4薬)、CG
BQ細胞(ガチョウ胚胸骨由来細胞二大日本#i)’i
i−用いても同様の効果を得た。
4. After 10 days of culture. OX 10 cells/11I
Obtain the cell density of tgel. Instead of HEL cells, M
Lg cells (ddY mouse lung cells two major Japanese M4 drugs), CG
BQ cells (goose embryo sternum-derived cells, two major Japanese #i)'i
A similar effect was obtained using i-.

実施例2 実施例1の液滴を形成する時、空気層流を用いて平均粒
径600μmのカプセルを形成場せた。
Example 2 When forming the droplets of Example 1, a laminar air flow was used to form capsules with an average particle size of 600 μm.

得られ友カプセルを増殖培地中で攪拌培養を行なつ友と
ころ、培養10日目で2.OX 10’ cells/
dgelの細胞密度を得た。
The obtained capsules were cultured with agitation in a growth medium, and on the 10th day of culture, 2. OX 10' cells/
The cell density of dgel was obtained.

実施例3 実施例2のHEL細胞のかわ’)I/C7”  (Fl
ow)7000(ヒト胎児包皮由来細胞二大日本展薬)
を使い、カルボキシメチルセルロースナトリウムのかわ
、9にアルギン酸ナトリウムを用いてカプセルを作製し
た。
Example 3 HEL cell membrane of Example 2) I/C7'' (Fl
ow) 7000 (Human fetal foreskin-derived cells, two major Japanese pharmaceuticals)
Capsules were prepared using sodium carboxymethylcellulose glue and sodium alginate in 9.

得られ次カプセルを攪拌培養したところ、培養14日目
で5.OX 10丁cells/m gelの細胞密度
に到達した。
When the obtained capsules were cultured with stirring, 5.5% was obtained on the 14th day of culture. A cell density of OX 10 cells/m gel was reached.

実施例4 実施例2のHEL細胞をニワ) +7胚軟骨細胞にかえ
、イータA/ (Eagle’s ) M E Mのか
わシにノーム(Ham’r、 ) F’−12を用いて
カプセルを作製し友。
Example 4 The HEL cells of Example 2 were replaced with Eagle's +7 embryonic chondrocytes, and capsules were made using Ham'r F'-12 in Eagle's MEM. Created friend.

得られ之カプセルをウシ胎児血清10チを含むハム(H
am’s ) F −12培地中で攪拌培養を行なった
ところ、培養14日目で1.OX 10’ cells
/wtgetの細胞密度を得た。
The resulting capsules were mixed with ham (H) containing 10 grams of fetal bovine serum.
Am's) When agitation culture was performed in F-12 medium, 1. OX 10' cells
/wtget cell density was obtained.

実施例5 実施例1のHEL細胞を乳腺上皮細胞にかえ、イーグル
(Eagle’s ) M E Mのかわp[10%ウ
シ胎児血清を含んだメディウム(Medium ) 1
99Kかえカプセルを作製し友。得られtカプセルをウ
シ胎児血清took含むメディウム(Medium)1
99中で7日間攪拌培養し、最終到達密度4.Ox 1
0’ cells/a(gelを得友。
Example 5 The HEL cells of Example 1 were replaced with mammary gland epithelial cells, and Eagle's MEM glue [Medium 1 containing 10% fetal bovine serum] was used.
A friend who made a 99K capsule. Medium 1 containing the obtained T capsule with fetal bovine serum took
99 for 7 days with stirring to reach a final density of 4. Ox 1
0' cells/a (get the gel.

実施例6 実施例1のHEL細胞を培養血管平滑筋細胞にかえ、カ
プセルを作製し次。得られ友カプセルを増殖培地中で7
日間培養し、最終到達密度2.0×1 ロ’  cel
ls/sd  gel  f 得1ヒ。
Example 6 The HEL cells in Example 1 were replaced with cultured vascular smooth muscle cells, and capsules were prepared. The obtained tomo capsules were grown in growth medium for 7 days.
Culture for 1 day and reach a final density of 2.0×1 cell.
ls/sd gel f 1hi.

実施例7 ウシ皮膚をペプシン処理して抽出し几アテロコラーゲン
全1を中K 3.OIR9含むp H3,0の溶液14
−に、実施例1のA液2−を加え、 NaOHでpH7
,Oic F整し、さらに、CV−1細胞(アフリカミ
ドリザル腎由来二人日本M栗)t−単層培養し。
Example 7 Bovine skin was treated with pepsin and extracted, and a total of atelocollagen was extracted. 3. Solution 14 with pH 3.0 containing OIR9
-, add solution A 2- of Example 1, and adjust the pH to 7 with NaOH.
, OicF, and further cultured in monolayer of CV-1 cells (Japanese M chestnut derived from African green monkey kidney).

トリプシン−エチレンジアミン四酢酸二ナトリウム処理
した細胞si液(2,OX 10’ cells/d 
)2−を加え、さらに、カルボキシメチルセルロースナ
トリウムの5チ水溶液2−を加え、カプセルを作製し友
。得られ次カプセルをウシ胎児血清10%を含むイーグ
ル(Eagle’s ) M E M培地中テ10日間
培養し、最終到達密度4.OX 10” cells/
sdgetを得友。
Trypsin-ethylenediaminetetraacetic acid disodium treated cell SI fluid (2,OX 10' cells/d
) Add 2-, and then add 5-di aqueous solution 2- of sodium carboxymethyl cellulose to prepare capsules. The resulting capsules were cultured in Eagle's MEM medium containing 10% fetal bovine serum for 10 days to reach a final density of 4. OX 10” cells/
I got sdget as a friend.

実施例8 実施例7のウシ皮膚をペプシン処理して抽出して得tア
テロコラーゲンのかわ5に、ラットvを酢酸で抽出して
得7を酸可溶性コラーゲンを用いてカプセルを作製した
。得られたカプセルを増殖培地中で12日間培養し、最
終到達濃度2.OX 10’cells 7m gel
 f得次。
Example 8 Capsules were prepared using atelocollagen glue 5 obtained by treating and extracting the bovine skin of Example 7 with pepsin and acid-soluble collagen obtained by extracting rat v with acetic acid. The resulting capsules were cultured in growth medium for 12 days to reach a final concentration of 2. OX 10'cells 7m gel
f Tokuji.

実施例9 メディウム(Medium ) 199粉末(ギプコ)
100p、ゲンタマイシン5009を蒸留水1tK溶解
し、濾過滅菌し文。この溶液をDとした。
Example 9 Medium 199 powder (Gipco)
100 p, gentamicin 5009 was dissolved in 1 tK of distilled water, filtered and sterilized. This solution was designated as D.

実施例2のA液のかわシKDiを用い、HEL細胞のか
わシにAYa(ヒト羊膜由来上皮細胞二大日本裂薬)を
用いてカプセルを作製し友。得られたカプセルを増殖培
地中で攪拌培養し、7日間で3、OX 10・cell
s /−gelの細胞密度を得几。
Capsules were prepared by using KDi from Example 2 and AYa (Human Amnion Derived Epithelial Cells) for HEL cells. The obtained capsules were cultured with stirring in a growth medium, and 3, OX 10 cells were grown in 7 days.
Obtain a cell density of s/-gel.

実施例10 0.08 N水酸化ナトリウム水溶液100−にN−ヒ
ドロキシエチルピペラジン−N’−2−エタンスルホン
酸4.77 tを溶かし、濾過滅菌し定。この溶1夜を
Eとした。
Example 10 4.77 t of N-hydroxyethylpiperazine-N'-2-ethanesulfonic acid was dissolved in 100% of a 0.08 N aqueous sodium hydroxide solution, and sterilized by filtration. This melting overnight was designated as E.

実施例1のB液のかわりにEak用い、カプセルを作成
し友。得られたカプセルを増殖培地中で攪拌培養し I
Q日日間1.OX 10’ cells/1ntgel
の細胞密度を得友。
Use Eak instead of liquid B in Example 1 to make capsules. The obtained capsules were cultured with stirring in a growth medium.
Q days 1. OX 10' cells/1ntgel
Obtain a cell density of .

比較例 Cellmatrix I A (Mr田ゼラチン社m
 、 3.Om9/l、pH3,0)21−に実施例1
のA液3−1B液3−を氷冷下順次加え、ざらに単層培
養し沈HEL細胞(大日本製薬)を常法により、濾過滅
菌したトリプシン−エチレンジアミン四酢酸二す) I
J ラム/P B S (−) (ダルベツコ)溶液で
はがし定細胞s ri液(4,9X 10’ cell
s/d ) 3 ttk加え、均一に混合し友、得られ
7を懸濁液を96穴マルチプレートに300μtずつ滴
下し友。その後37Cで10分間靜装し、ゲル1ヒを行
なつ友。
Comparative Example Cellmatrix IA (Mr. Gelatin Co., Ltd.)
, 3. Om9/l, pH 3,0) Example 1 to 21-
Solution A 3-1 and Solution B 3- were added sequentially under ice-cooling, cultured in a monolayer on a colander, and precipitated HEL cells (Dainippon Pharmaceutical Co., Ltd.) were sterilized by filtration using trypsin-ethylenediaminetetraacetic acid (I).
Peel off fixed cells with J Lamb/PB S (-) (Dulbetzko) solution and remove with SR solution (4.9X 10' cells).
s/d) 3ttk, mix uniformly, and drop the resulting suspension into a 96-well multi-plate in 300 μt portions. After that, I left it at 37C for 10 minutes and did a gel session.

マルチプレートからコラーゲンゲルビーズを取シ出し、
イータk(Eagle’s) MEM 100−中で攪
拌培養を行なつ友。コラーゲンビーズは経日的に収縮し
、6日後のセル密度は6.OX 10Scells/s
dgelであり、細胞の増殖はほとんど認められなかつ
之。
Remove the collagen gel beads from the multi-plate,
Eta k (Eagle's) MEM 100 - A companion for performing agitation culture in MEM 100-. Collagen beads shrink over time, and the cell density after 6 days was 6. OX 10 Cells/s
dgel, and almost no cell proliferation was observed.

Claims (6)

【特許請求の範囲】[Claims] (1)動物細胞、該動物細胞培養用培地およびコラーゲ
ンより成るゲル状組成物を、ポリアニオン多糖類または
その塩の単独もしくはそれらの混合物を基材とする流動
体と、可溶性キチン誘導体またはその塩の溶液との接触
により形成された皮膜で包括したカプセル。
(1) A gel composition consisting of animal cells, the animal cell culture medium, and collagen is combined with a fluid based on a polyanionic polysaccharide or a salt thereof or a mixture thereof, and a soluble chitin derivative or a salt thereof. A capsule surrounded by a film formed by contact with a solution.
(2)動物細胞が接着依存性細胞である特許請求の範囲
第1項記載のカプセル。
(2) The capsule according to claim 1, wherein the animal cell is an adhesion-dependent cell.
(3)動物細胞が接着依存性正常細胞である特許請求の
範囲第1項記載のカプセル。
(3) The capsule according to claim 1, wherein the animal cells are adhesion-dependent normal cells.
(4)動物細胞がヒト由来の接着依存性正常細胞である
特許請求の範囲第1項記載のカプセル。
(4) The capsule according to claim 1, wherein the animal cells are human-derived adhesion-dependent normal cells.
(5)可溶性キチン誘導体がキトサンである特許請求の
範囲第1項ないし第4項のいずれかに記載のカプセル。
(5) The capsule according to any one of claims 1 to 4, wherein the soluble chitin derivative is chitosan.
(6)コラーゲンの濃度が0.1%より大きく0.5%
より小さい特許請求の範囲第1項ないし第5項のいずれ
かに記載のカプセル。
(6) Collagen concentration is greater than 0.1% and 0.5%
A capsule according to any of claims 1 to 5 which is smaller.
JP61144784A 1986-06-23 1986-06-23 Collagen-containing capsule Pending JPS633786A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61144784A JPS633786A (en) 1986-06-23 1986-06-23 Collagen-containing capsule

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61144784A JPS633786A (en) 1986-06-23 1986-06-23 Collagen-containing capsule

Publications (1)

Publication Number Publication Date
JPS633786A true JPS633786A (en) 1988-01-08

Family

ID=15370363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP61144784A Pending JPS633786A (en) 1986-06-23 1986-06-23 Collagen-containing capsule

Country Status (1)

Country Link
JP (1) JPS633786A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01245848A (en) * 1988-03-29 1989-10-02 Snow Brand Milk Prod Co Ltd Production of capsule body with film of controllable permeability
WO1989010397A1 (en) * 1988-04-18 1989-11-02 Nitta Gelatin Inc. Process for culturing animal cells on a large scale and process for preparing supporting substrate for that process
JP2594367B2 (en) * 1988-04-18 1997-03-26 新田ゼラチン株式会社 Mass production of animal cells and production of support substrate for culture

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01245848A (en) * 1988-03-29 1989-10-02 Snow Brand Milk Prod Co Ltd Production of capsule body with film of controllable permeability
JPH0549335B2 (en) * 1988-03-29 1993-07-26 Snow Brand Milk Products Co Ltd
WO1989010397A1 (en) * 1988-04-18 1989-11-02 Nitta Gelatin Inc. Process for culturing animal cells on a large scale and process for preparing supporting substrate for that process
EP0364606A1 (en) * 1988-04-18 1990-04-25 Nitta Gelatin Inc. Process for culturing animal cells on a large scale and process for preparing supporting substrate for that process
US5264359A (en) * 1988-04-18 1993-11-23 Nitta Gelatin Inc. Methods for large-scale cultivation of animal cells and for making supporting substrata for the cultivation
EP0364606B1 (en) * 1988-04-18 1994-03-16 Nitta Gelatin Inc. Process for culturing animal cells on a large scale and process for preparing supporting substrate for that process
JP2594367B2 (en) * 1988-04-18 1997-03-26 新田ゼラチン株式会社 Mass production of animal cells and production of support substrate for culture

Similar Documents

Publication Publication Date Title
US4565580A (en) Substrate consisting of regenerated collagen fibrils and method of manufacturing same
JP4834540B2 (en) RGD-enriched gelatin-like protein with enhanced cell binding
US6140089A (en) Chitosan core matrix containing cells encapsulated in a thermoplastic semipermeable membrane
JPS5816693A (en) Production of substance produced by bacteria
KR102102153B1 (en) A bead for cell encapsulation and culture based on decellularized tissue, and use thereof
Wang et al. Cellular shellization: Surface engineering gives cells an exterior
CN106470666A (en) Microcapsule encapsulation technology and products thereof
JPH03500721A (en) Encapsulation of biological materials within semipermeable membranes
JPS59205985A (en) Recovery of non-secretory substance produced from cell
JP3951148B2 (en) Artificial skin containing skin appendage-like structure and method for producing the same
WO1989010397A1 (en) Process for culturing animal cells on a large scale and process for preparing supporting substrate for that process
JPS633786A (en) Collagen-containing capsule
JP5850416B2 (en) Method for producing cell tissue
JP7416185B2 (en) Method for manufacturing three-dimensional cell structures
CN105980549A (en) Capsules containing cells with blood-forming potential
JPS6225974A (en) Gelatinous composition consisting of collagen
JPH0581A (en) Carrier for cell culture and culture
JP2021153441A (en) Carrier for cell culture and cell culture method
CA1280381C (en) Entrapment of anchorage-dependent cells
JPS62171680A (en) Culture of animal cell
WO1987002056A1 (en) Method of obtaining microcarriers for cultivation of cells and microcarriers obtained by that method
JPS62262993A (en) Encapsulation of biologically active substance
US20220380723A1 (en) Methods to produce defined, spherical, bio-degradable macroporous microcarrier/hydrogels for cellular agriculture
WO2021065665A1 (en) Method for producing three-dimensional cell structure
WO2021039610A1 (en) Composition comprising microcapsule and cell structure